Lipid lowering, at least with statins, is beneficial in patients with dyslipidemias for both primary and secondary prevention of coronary heart disease.
A number of noncardiovascular benefits to statin therapy have been suggested. Many of these reflect associations in observational studies and may be due to confounding and/or bias.
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. - PubMed - NCBI
Statins do not appear to increase or decrease the risk of cancer.
Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. - PubMed - NCBI
Some observational studies have suggested that statins may decrease the risk of dementia and at least one small randomized trial has suggested that statins may slow the progression of dementia.
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. - PubMed - NCBI
Post-hoc analyses of clinical trials have raised the possibility that statins may be of some benefit in preserving renal function, both in patients with moderate chronic renal insufficiency and in patients with normal renal function．
risk of incident pneumonia (HR0.83, CI 0.69-1.00)
risk of sepsis (HR 1.21, CI 0.82-1.78)
all infections (HR 0.98, CI 0.94-1.03)
severe infections (HR 0.90, CI 0.79-1.03)
Systematic review and meta-analysis of randomised placebo controlled trials.
Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. - PubMed - NCBI
11 randomized trials of statins (n = 30,947) found no effect of statin therapy on infections (relative risk [RR] 1.00, 95% CI 0.96-1.05) or infection related mortality (RR 0.97, CI 0.83-1.13)